Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 320 participants.

Also called NCT03041259

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 1/2
Enrolled
  • 320 participants (planned count) (from the registry)
Sponsor
Reven Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT03041259
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03041259. Randomized; single masking; primary purpose treatment. Start 2020-01 (anticipated); primary completion 2022-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction
Acronym
RESTORE
Condition
Critical Limb Ischemia
Condition
Peripheral Arterial Disease
Intervention (Drug)
Rejuveinix Low Dose
Intervention (Drug)
Rejuveinix High Dose
Lead sponsor
Reven Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03041259
Content hash
016001483dd07516ed9c2b7853ee95dd1fbdb24e7c080813aa2a9eb1594e6df9